Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Dana, Hilt"'
Autor:
Peter A. Ljubenkov, Mary Koestler, Florence Pasquier, Dana Hilt, Beth Ann Haynes, Renaud La Joie, Lauren Edwards, Bradley F. Boeve, Jacob Hesterman, Ira J. Goodman, Leonardo Iaccarino, Rik Vandenberghe, Catherine J. Mummery, Marco Onofrj, Sophie Auriacombe, Henry Riordan, Gerhard Koenig, Julio C. Rojas, Hans J Moebius, Adam L. Boxer, Giovanni B. Frisoni, Scott M. McGinnis, Gary Wisniewski, Ken Marek, Didier Hannequin, Murray Grossman, John C. van Swieten, Holger Patzke, Isabelle Le Ber, Baruch Harris, Barbara Borroni
Publikováno v:
JAMA Network Open
JAMA Network Open, American Medical Association, 2021, 4 (9), pp.e2125584. ⟨10.1001/jamanetworkopen.2021.25584⟩
JAMA Network Open, 2021, 4 (9), pp.e2125584. ⟨10.1001/jamanetworkopen.2021.25584⟩
JAMA network open, 4(9):25584. American Medical Association
JAMA Network Open, American Medical Association, 2021, 4 (9), pp.e2125584. ⟨10.1001/jamanetworkopen.2021.25584⟩
JAMA Network Open, 2021, 4 (9), pp.e2125584. ⟨10.1001/jamanetworkopen.2021.25584⟩
JAMA network open, 4(9):25584. American Medical Association
Key Points Question What is the safety, tolerability, pharmacodynamic, and pharmacokinetic profile of the histone deacetylase inhibitor FRM-0334 in participants with progranulin gene (GRN) haploinsufficiency? Findings In this randomized placebo-contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85461c1fe333ce116f09c9a714feab20
http://hdl.handle.net/20.500.12278/123771
http://hdl.handle.net/20.500.12278/123771
Autor:
Gordon Loewen, Karen Broekhuizen, Geert Jan Groeneveld, Anne Catrien Baakman, Dana Hilt, Marieke L. de Kam, Ricardo Alvarez-Jimenez
Publikováno v:
Alzheimer's and Dementia: Translational Research and Clinical Interventions, 5, 89-98. Elsevier Inc.
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Baakman, A C, Alvarez-Jimenez, R, Loewen, G, de Kam, M L, Broekhuizen, K, Hilt, D C & Groeneveld, G J 2019, ' No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model ', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 5, pp. 89-98 . https://doi.org/10.1016/j.trci.2019.02.002
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Baakman, A C, Alvarez-Jimenez, R, Loewen, G, de Kam, M L, Broekhuizen, K, Hilt, D C & Groeneveld, G J 2019, ' No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model ', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 5, pp. 89-98 . https://doi.org/10.1016/j.trci.2019.02.002
Introduction Donepezil is a widely used cholinesterase inhibitor in the management of Alzheimer's disease. Despite large-scaled evidence for its efficacy, elevated peripheral ACh levels often lead to side effects and are dose limiting. The present ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fbf2a2ba7a2f5bc4f0977a9a900e7e6
https://doi.org/10.1016/j.trci.2019.02.002
https://doi.org/10.1016/j.trci.2019.02.002
Autor:
Trina W. Walker, Anastasia Georgiades, Dana Hilt, Vicki G. Davis, George M. Haig, Eduardo Dunayevich, Michael Sand, Daniel Umbricht, Richard S.E. Keefe, Anzalee Khan, Antony Loebel, Alexandra S. Atkins
Publikováno v:
Schizophrenia Research. 190:172-179
The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9b12f99549270f73642d04a5b9fc9d
https://doi.org/10.1016/j.schres.2017.03.040
https://doi.org/10.1016/j.schres.2017.03.040
Autor:
Marco Onofrj, Holger Patzke, Murray Grossman, Rik Vandenberghe, Henry Riordan, Isabelle Le Ber, Sophie Auriacombe, Jacob Hesterman, Hans J Moebius, Gerhard Koenig, Giovanni B. Frisoni, Adam L. Boxer, Bradley F. Boeve, Gary Wisniewski, Ken Marek, Ira J. Goodman, Florence Pasquier, Didier Hannequin, Baruch Harris, Barbara Borroni, Scott M. McGinnis, Dana Hilt, John C. van Swieten, Catherine J. Mummery
Publikováno v:
Alzheimer's & Dementia. 15:P1231-P1232
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b37d602fc3682ef9049e843e9680266
https://doi.org/10.1016/j.jalz.2019.06.4746
https://doi.org/10.1016/j.jalz.2019.06.4746
Autor:
Hans J Moebius, Richard S.E. Keefe, Dana Hilt, Herbert A Meltzer, Gerhard Koenig, Ilise Lombardo, Nancy Dgetluck, Maria Gawryl
Publikováno v:
Neuropsychopharmacology. 40:3053-3060
Encenicline is a novel, selective α7 nicotinic acetylcholine receptor agonist in development for treating cognitive impairment in schizophrenia and Alzheimer's disease. A phase 2, double-blind, randomized, placebo-controlled, parallel-design, multin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcd73351f99007a72a2169943276c083
https://doi.org/10.1038/npp.2015.176
https://doi.org/10.1038/npp.2015.176
Autor:
Thomas D. Patterson, Dana Hilt, Philip D. Harvey, Nathan B. Spagnola, Richard S.E. Keefe, Stacy A. Ruse, Meera Narasimhan, Vicki G. Davis, Nancy Dgetluck
Publikováno v:
European Neuropsychopharmacology. 25:176-184
Cognitive functioning can be assessed with performance-based assessments such as neuropsychological tests and with interview-based assessments. Both assessment methods have the potential to assess whether treatments for schizophrenia improve clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f2c39d5c46eb76f5f70c14dbda7016a
https://doi.org/10.1016/j.euroneuro.2014.06.009
https://doi.org/10.1016/j.euroneuro.2014.06.009
Publikováno v:
Fatigue: Biomedicine, Health & Behavior. 2:231-246
Fatigue is reflected in a broad array of symptoms that can be particularly impactful in patients with central nervous system (CNS) disorders. Fatigue symptoms can present as core components of the underlying CNS disorder, as part of co-morbid medical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0bae657a63570e974f294d4a6c68cf5
https://doi.org/10.1080/21641846.2014.959802
https://doi.org/10.1080/21641846.2014.959802
Autor:
David, Daniel, Amir, Kalali, Mark, West, David, Walling, Dana, Hilt, Nina, Engelhardt, Larry, Alphs, Antony, Loebel, Kim, Vanover, Sarah, Atkinson, Mark, Opler, Gary, Sachs, Kari, Nations, Chris, Brady
Publikováno v:
Innovations in clinical neuroscience. 13(1-2)
This paper summarizes the results of the CNS Summit Data Quality Monitoring Workgroup analysis of current data quality monitoring techniques used in central nervous system (CNS) clinical trials. Based on audience polls conducted at the CNS Summit 201
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5f8a59fabda7a7cb9c290708580ce4de
https://pubmed.ncbi.nlm.nih.gov/27413584
https://pubmed.ncbi.nlm.nih.gov/27413584
Autor:
Nick P. van Goethem, Frank G. Boess, Gerhard Konig, Olga A.H. Reneerkens, Dana Hilt, Richard Chesworth, Daniel Bertrand, Jos Prickaerts, Gideon Shapiro, Sonia Bertrand, Maria Gawryl, Christoph Methfessel, Dorothy G. Flood
Publikováno v:
Neuropharmacology, 62(2), 1099-1110. Elsevier Science
EVP-6124, (R)-7-chloro-N-quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, is a novel partial agonist of alpha 7 neuronal nicotinic acetylcholine receptors (nAChRs) that was evaluated here in vitro and in vivo. In binding and functional experiments,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8305e4e82aad59c974ceb6892adb22c5
https://doi.org/10.1016/j.neuropharm.2011.10.024
https://doi.org/10.1016/j.neuropharm.2011.10.024
Autor:
Philip D. Harvey, Alexandra S. Atkins, Richard S.E. Keefe, Vicki G. Davis, Owen Hagino, Dana Hilt, Daniel Umbricht, Stephen R. Marder, George M. Haig
Publikováno v:
JAMA Psychiatry. 74:807
Importance Patients’ previous experience with performance-based cognitive tests in clinical trials for cognitive impairment associated with schizophrenia can create practice-related improvements. Placebo-controlled trials for cognitive impairment a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f195d94a303a0ceefa7d5a8ad48a7542
https://doi.org/10.1001/jamapsychiatry.2017.1574
https://doi.org/10.1001/jamapsychiatry.2017.1574